SAN MATEO, Calif., April 27, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced it will hold a conference call on Thursday, May 3, 2012, at 4:30 p.m. ET (1:30 p.m. PT) to report results for its first quarter ended March 31, 2012.
The conference call will be hosted by Ronald Martell, President and Chief Executive Officer, and Stephen Ghiglieri, Executive Vice President, Chief Operating Officer and Chief Financial Officer.
To participate, please dial 1-877-407-0784 (U.S.) or 1-201-689-8560 (International). To access the live webcast please visit the Investor Relations section on the corporate website at http://www.neurogesx.com.
A replay of the conference call will be available beginning May 3, 2012 at 7:30 p.m. ET (4:30 p.m. PT) and ending on May 17, 2012 by dialing 1-877-870-5176 (U.S.) or 1-858-384-5517 (International) with Conference ID Number: 393083. A replay of the webcast will also be available on the corporate website through June 3, 2012.
About NeurogesX, Inc.
NeurogesX, Inc. (Nasdaq:NGSX) is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies to address unmet medical needs and improve patients' quality of life.
The Company's lead product, Qutenza®, is currently approved in the United States and the European Union. Qutenza is available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European affiliate of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.
The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 clinical trials and one Phase 2 clinical trial in PHN patients, and the Company believes that NGX-1998 is ready to enter Phase 3 development. The Company anticipates that an End-of-Phase 2 meeting for NGX-1998 with the U.S. Food and Drug Administration will occur in the third quarter of 2012.
The Company's early-stage pipeline includes pre-clinical compounds which include a number of prodrugs of acetaminophen. The Company has evaluated certain of these compounds in vitro and in vivo.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: readiness of NGX-1998 to enter into Phase 3 development and the timing of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: potential insufficiency of data obtained for NGX-1998 to support progressing such product candidate into Phase 3 development; delays in the End-of-Phase 2 meeting with the FDA; difficulties or delays in further clinical development of NGX-1998; difficulties or delays in obtaining additional resources for continuing operations in general and for development of NGX-1998 in particular; potential de-listing from the NASDAQ Global Market; and development by others of competitive therapies for indications that NeurogesX' product and product candidates target. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.